In this webinar Dr. Rupa Patel discusses pharmacy and financing considerations for initiating and managing PrEP. Dr. Patel, Assistant Professor of Medicine and Director of the PrEP for HIV Program at the Washington University of Medicine in St. Louis, will explore these topics and provide guidance for health centers providing PrEP to their patients.
Learning Resources — Pre-Exposure Prophylaxis (PrEP)
Pre-and-Post Exposure Prophylaxis
In this series of videos, Dr. Kevin Ard will discuss various aspects of PrEP and PEP.
This video course is not currently eligible for CME credit.
Transgender Women and Pre-exposure Prophylaxis for HIV Prevention: What We Know and What We Still Need to Know
The National Center for Innovation in HIV Care
Transgender women are at elevated risk of becoming infected with HIV. Pre-exposure prophylaxis for HIV prevention (PrEP) is effective in reducing the risk of HIV infection among men who have sex with men (MSM), heterosexual men and women, and people who inject drugs (PWID). While transgender women have been included in some clinical trials of PrEP, no study has shown PrEP to be effective in reducing transgender women’s HIV risk.
Protecting Yourself from HIV through Pre-Exposure Prophylaxis (PrEP): What You Need to Know
The Food & Drug Administration (FDA) recently approved the use of an HIV treatment medication for HIV-negative people at high risk of getting HIV through sexual exposure. Known as “pre-exposure prophylaxis”—or PrEP—this medication is a once-a-day pill to be used in combination with condoms and other safer sex behavioral strategies to reduce risk. Protecting Yourself from HIV through PrEP informs consumers about PrEP and how it works, as well as other ways they can work with their health care providers to protect themselves against HIV.
